{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:32:17Z","timestamp":1791912737845,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.bbmt.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T18:13:10Z","timestamp":1402942390000},"page":"1877-1884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":75,"title":["Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A Review"],"prefix":"10.1016","volume":"20","author":[{"given":"Monzr M.","family":"Al-Malki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Mark","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2014.06.009_bib1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib2","series-title":"WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissues","first-page":"256","article-title":"Plasmablastic lymphoma","author":"Stein","year":"2008"},{"key":"10.1016\/j.bbmt.2014.06.009_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clml.2011.03.008","article-title":"HIV-negative plasmablastic lymphoma: not in the mouth","volume":"11","author":"Castillo","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2014.06.009_bib4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3109\/10428194.2010.516040","article-title":"Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma","volume":"51","author":"Castillo","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.06.009_bib5","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2009.016113","article-title":"Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype","volume":"95","author":"Montes-Moreno","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.009_bib6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-2-47","article-title":"Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma","volume":"2","author":"Chang","year":"2009","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib7","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3779.3779","article-title":"Gene expression analysis of plasmablastic lymphoma identifies down-regulation of B-cell receptor signaling and additional unique transcriptional programs disordered","volume":"122","author":"Chapman-Fredricks","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/PAS.0b013e3181f3e29f","article-title":"IG\/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas","volume":"34","author":"Valera","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib9","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1309\/AJCPFUR1BK0UODTS","article-title":"Plasmablastic lymphomas with MYC\/IgH rearrangement: report of three cases and review of the literature","volume":"132","author":"Bogusz","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/asheducation-2013.1.575","article-title":"Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification","volume":"2013","author":"Ott","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2014.06.009_bib11","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/blood-2010-09-297879","article-title":"Double-hit B-cell lymphomas","volume":"117","author":"Aukema","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1100\/tsw.2011.59","article-title":"Plasmablastic lymphoma: a systematic review","volume":"11","author":"Castillo","year":"2011","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bbmt.2014.06.009_bib13","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.06.009_bib14","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","article-title":"Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study","volume":"27","author":"Schommers","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.bbmt.2014.06.009_bib15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.1801.1801","article-title":"Plasmablastic lymphoma is curable. The HAART era. A 10-year retrospective by the AIDS Malignancy Consortium (AMC)","volume":"122","author":"Noy","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib16","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4310.4310","article-title":"Plasmablastic lymphoma: 28 patient single institution experience","volume":"122","author":"Patel","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib17","article-title":"Plasmablastic lymphoma among HIV-positive patients: results of a single centre's experience","author":"Cattaneo","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2014.06.009_bib18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.leukres.2011.06.023","article-title":"Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review","volume":"35","author":"Liu","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2014.06.009_bib19","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2014.06.009_bib21","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/annonc\/mdh399","article-title":"CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogeneous spectrum in both HIV-positive and -negative patients","volume":"15","author":"Teruya-Feldstein","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib22","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib23","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/blood-2002-11-3589","article-title":"Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology","volume":"101","author":"Little","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib24","unstructured":"Phase II study of dose-adjusted EPOCH-rituximab in adults with untreated Burkitt lymphoma and c-MYC+ diffuse large B-cell lymphoma. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01092182."},{"key":"10.1016\/j.bbmt.2014.06.009_bib25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.2010.30.0038","article-title":"Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone","volume":"28","author":"Bibas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib26","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2009.01235.x","article-title":"AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib","volume":"82","author":"Bose","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3816\/CLML.2010.n.074","article-title":"Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma","volume":"10","author":"Lipstein","year":"2010","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2014.06.009_bib28","first-page":"287","article-title":"Bortezomib in plasmablastic lymphoma: a case report and review of the literature","volume":"36","author":"Saba","year":"2013","journal-title":"Onkologie"},{"key":"10.1016\/j.bbmt.2014.06.009_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/01.pas.0000126781.87158.e3","article-title":"Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities","volume":"28","author":"Colomo","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.anndiagpath.2005.07.009","article-title":"Plasmablastic lymphoma: a clinicopathologic correlation","volume":"10","author":"Folk","year":"2006","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib32","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/modpathol.3800355","article-title":"Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles","volume":"18","author":"Vega","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2003.09.015","article-title":"Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission","volume":"10","author":"Vose","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.009_bib36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2014.06.009_bib37","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V90.10.3844","article-title":"Results of high-dose therapy and autologous bone marrow\/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International index high and high-intermediate risk group","volume":"90","author":"Nademanee","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib38","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib39","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib40","first-page":"1100","article-title":"High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease","volume":"89","author":"Gabarre","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.009_bib41","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood.V98.13.3857","article-title":"Autologous stem cell transplantation for HIV-associated lymphoma","volume":"98","author":"Krishnan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib42","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas","volume":"105","author":"Krishnan","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbmt.2010.03.019","article-title":"HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for Non Hodgkin Lymphoma (NHL)","volume":"16","author":"Krishnan","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.009_bib44","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1200\/JCO.2003.06.039","article-title":"High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy","volume":"23","author":"Re","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib45","first-page":"247a","article-title":"Long-term survival after autologous stem cell transplantation in AIDS related lymphoma patients","volume":"102","author":"Diez Martin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib46","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/(SICI)1097-0142(19960515)77:10<2127::AID-CNCR25>3.0.CO;2-W","article-title":"Second line chemotherapy in human immunodeficiency virus related non-Hodgkin\u2019s lymphoma","volume":"77","author":"Tirelli","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.06.009_bib47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/1097-0142(20010701)92:1<200::AID-CNCR1310>3.0.CO;2-A","article-title":"Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients","volume":"92","author":"Spina","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2014.06.009_bib48","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00042560-200112150-00002","article-title":"High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS related non-Hodgkin\u2019s lymphoma","volume":"28","author":"Bi","year":"2001","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bbmt.2014.06.009_bib49","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib50","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.joms.2005.12.039","article-title":"Spontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case report","volume":"65","author":"Armstrong","year":"2007","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.bbmt.2014.06.009_bib51","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.3324\/haematol.10933","article-title":"AIDS-related plasmablastic lymphoma of the oral cavity associated with an IGH\/MYC translocation\u2013treatment with autologous stem-cell transplantation in a patient with severe hemophilia-A","volume":"92","author":"Dawson","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.009_bib52","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.4081\/rt.2011.e11","article-title":"Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous stem cell transplantation and highly active antiretroviral therapy","volume":"3","author":"Goto","year":"2011","journal-title":"Rare Tumors"},{"key":"10.1016\/j.bbmt.2014.06.009_bib53","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and Etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib54","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2002-03-0989","article-title":"Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection","volume":"100","author":"Spina","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib55","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV positive and HIV negative non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Diez-Martin","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib56","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1086\/652866","article-title":"Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma","volume":"50","author":"Simonelli","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bbmt.2014.06.009_bib57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/aid.2006.0071","article-title":"Short communication: Immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: might be better than expected?","volume":"23","author":"Resino","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.bbmt.2014.06.009_bib58","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High dose therapy and autologous peripheral blood stem cell transplantation for salvage treatment for AIDS related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors study with analysis of prognostic factors","volume":"114","author":"Re","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib59","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","article-title":"Autologous stem cell transplantation in patients with HIV related lymphoma","volume":"27","author":"Balsalobre","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib60","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.leu.2403206","article-title":"Diffuse large B-cell lymphomas with plasmablastic\/plasmacytoid features are associated with TP53 deletions and poor clinical outcome","volume":"18","author":"Simonitsch-Klupp","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2014.06.009_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2004.12.008","article-title":"HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation","volume":"33","author":"Serrano","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib62","first-page":"508","article-title":"International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin\u2019s lymphoma treated with CHOP: A multivariate study of 46 patients","volume":"83","author":"Navarro","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.009_bib63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e31802bb5d0","article-title":"Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors","volume":"44","author":"Miralles","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bbmt.2014.06.009_bib64","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Shen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib65","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin\u2019s lymphoma: updated results of the prospective study LNH87-2","volume":"15","author":"Haioun","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib66","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.3124.3124","article-title":"Early consolidation with high dose therapy and autologous stem cell transplantation in HIV-associated Non Hodgkin Lymphoma at high risk (aa-IPI 2-3), an interim report of a multicenter phase II trial","volume":"120","author":"Re","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib67","first-page":"285","article-title":"Bone marrow transplantation in an HIV positive thalassemia child following therapy with azidothymidine","volume":"75","author":"Angelucci","year":"1990","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2014.06.009_bib68","first-page":"277","article-title":"HIV infection in autologous and allogeneic bone marrow transplant patients: a retrospective analysis of the Marseille bone marrow transplant population","volume":"6","author":"Cooper","year":"1993","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.bbmt.2014.06.009_bib69","first-page":"49N","article-title":"Progression of human immunodeficiency virus type-1 infection after allogeneic marrow transplantation","volume":"88","author":"Bowden","year":"1990","journal-title":"Am J Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib70","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-111-12-973","article-title":"Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection: studies in a patient with non-Hodgkin lymphoma","volume":"111","author":"Holland","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bbmt.2014.06.009_bib71","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2249.2010.04312.x","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years","volume":"163","author":"Hutter","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bbmt.2014.06.009_bib72","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbmt.2009.03.023","article-title":"Allogeneic hematopoietic cell transplantation in HIV-positive patients with hematological disorders: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"15","author":"Gupta","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2014.06.009_bib73","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1182\/blood-2009-06-229666","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can","volume":"114","author":"Hamadani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2014.06.009_bib74","unstructured":"Allogeneic transplant in HIV patients (BMT CTN 0903), identifier NCT01410344. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01410344?term=Allogeneic+transplant+in+HIV+patients&rank=1."},{"key":"10.1016\/j.bbmt.2014.06.009_bib75","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/00002030-200307040-00030","article-title":"Epstein-Barr virus\u2013related plasmablastic lymphomas arising from long-standing sacrococcygeal cysts in immunosuppressed patients","volume":"17","author":"Ojanguren","year":"2003","journal-title":"AIDS"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879114003590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:16Z","timestamp":1761058096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879114003590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1083879114003590"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.009","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation for Plasmablastic Lymphoma: A Review","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}